Synapcell

SynapCell is a Brain-focused biotechnology company that provides drug developers with robust and unbiased endpoints on drug efficacy in vivo, at the preclinical step. We use quantitative, EEG-based methods to longitudinally monitor a drug effect on translational models, following clinical-like protocols. Our capabilities include dose-response studies, pharmacodynamics, biomarker identification and modulation, disease-modifying assays, model phenotyping, as well as phenotypic screening for lead selection and validation. Our expertise in Neuroscience covers Epilepsy, Parkinson's disease, Essential Tremors as well as information processing defects such as schizophrenia. Since 2005, our returning customers in USA, Japan, Korea or Europe helped the company establish a unique reputation on the market and is the basis for long-lasting successful business partnerships.